84 related articles for article (PubMed ID: 12496979)
41. [Experience in treating advanced prostate cancer with bladder outlet obstruction].
Sheng XJ; Zhu YJ; Ye M; Chen JH; Zhang L; Kong L
Ai Zheng; 2005 Oct; 24(10):1284-6. PubMed ID: 16219150
[TBL] [Abstract][Full Text] [Related]
42. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
[TBL] [Abstract][Full Text] [Related]
43. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate.
Autorino R; Damiano R; Di Lorenzo G; Quarto G; Perdonà S; D'Armiento M; De Sio M
Eur Urol; 2009 Apr; 55(4):922-9. PubMed ID: 19185975
[TBL] [Abstract][Full Text] [Related]
44. [Changes of urinary symptoms after transurethral resection of the prostate and its correlation with clinical parameters].
Zhao Z; Wang G; Na YQ
Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):957-9. PubMed ID: 17961379
[TBL] [Abstract][Full Text] [Related]
45. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup.
Hon NH; Brathwaite D; Hussain Z; Ghiblawi S; Brace H; Hayne D; Coppinger SW
J Urol; 2006 Jul; 176(1):205-9. PubMed ID: 16753403
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
47. Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia.
Ruszat R; Seitz M; Wyler SF; Müller G; Rieken M; Bonkat G; Gasser TC; Reich O; Bachmann A
BJU Int; 2009 Sep; 104(6):820-5. PubMed ID: 19239441
[TBL] [Abstract][Full Text] [Related]
48. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results.
Goya N; Ishikawa N; Ito F; Kobayashi C; Tomizawa Y; Toma H
J Urol; 2004 Sep; 172(3):1017-20. PubMed ID: 15311027
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
50. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
51. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.
Bachmann A; Schürch L; Ruszat R; Wyler SF; Seifert HH; Müller A; Lehmann K; Sulser T
Eur Urol; 2005 Dec; 48(6):965-71; discussion 972. PubMed ID: 16126327
[TBL] [Abstract][Full Text] [Related]
52. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.
Stovsky MD; Griffiths RI; Duff SB
J Urol; 2006 Oct; 176(4 Pt 1):1500-6. PubMed ID: 16952668
[TBL] [Abstract][Full Text] [Related]
53. [Transvesical radiofrequency needle ablation on prostatic benign hyperplasia].
Arustamov DL; Mukhtarov ShT; Arustamov LD
Urologiia; 2000; (6):34-7. PubMed ID: 11186320
[TBL] [Abstract][Full Text] [Related]
54. Transurethral ethanol ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up.
El-Husseiny T; Buchholz N
J Endourol; 2011 Mar; 25(3):477-80. PubMed ID: 21355774
[TBL] [Abstract][Full Text] [Related]
55. Transurethral needle ablation of the prostate: an initial Japanese clinical trial.
Murai M; Tachibana M; Miki M; Shiozawa H; Hirao Y; Okajima E
Int J Urol; 2001 Mar; 8(3):99-105. PubMed ID: 11260333
[TBL] [Abstract][Full Text] [Related]
56. [A new method of radiofrequency needle ablation of the prostate in the treatment of benign hyperplasia].
Mukhtarov ShT; Arustamov DL
Urologiia; 2002; (2):13-6. PubMed ID: 12077813
[TBL] [Abstract][Full Text] [Related]
57. Stone formation in the prostatic urethra after cryotherapy for prostate cancer.
Aus G; Bergdahl S; Hugosson J; Lundin SE
Urology; 1997 Oct; 50(4):615-7. PubMed ID: 9338745
[TBL] [Abstract][Full Text] [Related]
58. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report.
Savoca G; De Stefani S; Gattuccio I; Paolinelli D; Stacul F; Belgrano E
Eur Urol; 2001 Nov; 40(5):504-8. PubMed ID: 11752856
[TBL] [Abstract][Full Text] [Related]
59. Intraprostatic ethanol injection as an alternative therapy in patients with benign prostatic hyperplasia.
Espinoza AR
Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):158-164. PubMed ID: 30509604
[TBL] [Abstract][Full Text] [Related]
60. Ablation of canine prostate using transurethral intraprostatic absolute ethanol injection.
Zvara P; Karpman E; Stoppacher R; Esenler AC; Plante MK
Urology; 1999 Sep; 54(3):411-5. PubMed ID: 10475344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
